• Telix Pharmaceuticals partnered with Ekalia, an IBA-Framatome joint venture, to develop scalable U.S. astatine-211 production.
• The collaboration secures long-term, priority isotope access for its alpha therapy pipeline, including TLX102-Tx for glioblastoma and leptomeningeal disease.
• The first IBA alpha-beam cyclotron will be installed at the RLS Radiopharmacies site in Trevose, near Philadelphia.
• The partners will evaluate additional RLS installations as demand develops, with production capacity also intended for third-party academic and industry programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190130PRIMZONEFULLFEED9848109) on October 19, 2026, and is solely responsible for the information contained therein.